Genialis, a Boston, MA- and Ljubljana, Slovenia, based computational precision medicine company, raised $13M in Series A funding.
The round was led by Debiopharm Innovatoin Fund and Taiwania Capital with participation from previous investors First Star Ventures, Redalpine Venture Partners, Pikas, and P5 Health Ventures. Ita Lu of Taiwania and Hamzeh Abdul-Hadi of Debiopharm will join Genialis’ Board of Directors.
The company intends to use the funds to expand its proprietary ResponderID platform and build out its comprehensive collection of clinically validated biomarker models to provide pinpoint diagnoses for virtually every cancer patient.
Led by CEO Rafael Rosengarten, and CTO Miha Stajdohar, Ph.D., Genialis is a computational precision medicine company leveraging complex biology to find new ways to address disease. ResponderID, its machine-learning-driven disease modeling platform, delivers actionable biomarkers and optimally positions novel drugs to accelerate translational research, streamline drug development and ensure the best possible clinical care.
To date, Genialis has used ResponderID in collaboration with biopharma to analyze clinical trial data and inform future trial designs for numerous investigational drugs. The company also supports the commercialization of next-gen biomarker assays with several leading diagnostic firms.
Genialis is growing its teams in both the U.S. and Slovenia across business, operations, life science, and data science functions and expanding its advisory boards. The company is also investing in R&D collaborations with several leading cancer centers, hospital groups, and clinical academic labs.
FinSMEs
29/03/2023